Jacobs & Co. CA Sells 6,794 Shares of Pfizer Inc. (NYSE:PFE)

Jacobs & Co. CA decreased its position in Pfizer Inc. (NYSE:PFE) by 2.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 317,660 shares of the biopharmaceutical company’s stock after selling 6,794 shares during the quarter. Pfizer makes up approximately 1.4% of Jacobs & Co. CA’s portfolio, making the stock its 26th largest holding. Jacobs & Co. CA’s holdings in Pfizer were worth $11,651,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in PFE. BancFirst Trust & Investment Management increased its stake in Pfizer by 2.3% during the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock valued at $719,000 after acquiring an additional 398 shares during the period. Strategic Investment Advisors MI lifted its holdings in shares of Pfizer by 32.1% during the 1st quarter. Strategic Investment Advisors MI now owns 94,117 shares of the biopharmaceutical company’s stock worth $3,840,000 after acquiring an additional 22,879 shares during the period. State of Michigan Retirement System lifted its holdings in shares of Pfizer by 0.9% during the 1st quarter. State of Michigan Retirement System now owns 1,771,584 shares of the biopharmaceutical company’s stock worth $72,281,000 after acquiring an additional 15,900 shares during the period. MainStreet Investment Advisors LLC lifted its holdings in shares of Pfizer by 1.6% during the 1st quarter. MainStreet Investment Advisors LLC now owns 197,477 shares of the biopharmaceutical company’s stock worth $8,057,000 after acquiring an additional 3,099 shares during the period. Finally, Center For Asset Management LLC lifted its holdings in shares of Pfizer by 28.0% during the 1st quarter. Center For Asset Management LLC now owns 23,894 shares of the biopharmaceutical company’s stock worth $975,000 after acquiring an additional 5,228 shares during the period. 68.05% of the stock is currently owned by institutional investors.

Pfizer Stock Down 1.3 %

NYSE:PFE opened at $33.64 on Tuesday. The firm has a market capitalization of $189.93 billion, a price-to-earnings ratio of 8.95, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59. Pfizer Inc. has a twelve month low of $33.44 and a twelve month high of $54.93. The stock’s 50 day moving average price is $35.80 and its two-hundred day moving average price is $37.96. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.10. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. During the same period in the previous year, the business earned $2.04 EPS. Pfizer’s revenue for the quarter was down 54.1% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 3.33 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 5th. Investors of record on Friday, July 28th were paid a $0.41 dividend. The ex-dividend date of this dividend was Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a yield of 4.88%. Pfizer’s dividend payout ratio (DPR) is currently 43.62%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Jefferies Financial Group cut their target price on Pfizer from $40.00 to $38.00 in a research report on Wednesday, August 2nd. Barclays dropped their target price on shares of Pfizer from $40.00 to $38.00 in a research note on Tuesday, July 11th. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $45.00 to $41.00 and set a “neutral” rating for the company in a research note on Monday, July 17th. Morgan Stanley dropped their target price on shares of Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a report on Monday. Twelve analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $46.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.